Market Closed -
Nasdaq
04:00:00 2024-04-29 pm EDT
|
5-day change
|
1st Jan Change
|
65.5
USD
|
+0.21%
|
|
-0.18%
|
+18.79%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
733
|
348.4
|
771.5
|
655.9
|
1,052
|
1,374
|
-
|
-
|
Enterprise Value (EV)
1 |
733
|
348.4
|
771.5
|
655.9
|
1,052
|
1,294
|
1,186
|
1,374
|
P/E ratio
|
123
x
|
-15.4
x
|
-13.6
x
|
-13.2
x
|
64.9
x
|
50.9
x
|
31.9
x
|
19.9
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
3.55
x
|
1.67
x
|
3.57
x
|
2.07
x
|
2.16
x
|
2.57
x
|
2.39
x
|
2.26
x
|
EV / Revenue
|
3.55
x
|
1.67
x
|
3.57
x
|
2.07
x
|
2.16
x
|
2.42
x
|
2.06
x
|
2.26
x
|
EV / EBITDA
|
8.81
x
|
5.19
x
|
11.9
x
|
11.7
x
|
7.86
x
|
9.25
x
|
7.52
x
|
8.01
x
|
EV / FCF
|
-
|
-
|
1,008
x
|
-16.4
x
|
9.56
x
|
12.1
x
|
11.3
x
|
11.3
x
|
FCF Yield
|
-
|
-
|
0.1%
|
-6.11%
|
10.5%
|
8.29%
|
8.89%
|
8.86%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
11,886
|
11,996
|
16,742
|
16,304
|
19,083
|
20,980
|
-
|
-
|
Reference price
2 |
61.67
|
29.04
|
46.08
|
40.23
|
55.14
|
65.50
|
65.50
|
65.50
|
Announcement Date
|
2/27/20
|
3/9/21
|
3/15/22
|
3/9/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
206.5
|
208.5
|
216.1
|
316.4
|
486.8
|
534.7
|
575.6
|
609.3
|
EBITDA
1 |
83.16
|
67.12
|
64.84
|
55.86
|
133.8
|
139.8
|
157.8
|
171.5
|
EBIT
1 |
16.35
|
-16.02
|
-39.79
|
-35.28
|
46.97
|
51.27
|
63.18
|
74.4
|
Operating Margin
|
7.92%
|
-7.68%
|
-18.41%
|
-11.15%
|
9.65%
|
9.59%
|
10.98%
|
12.21%
|
Earnings before Tax (EBT)
1 |
3.157
|
-25.96
|
-56.06
|
-62.66
|
19.87
|
28.83
|
43.48
|
66.4
|
Net income
1 |
6.094
|
-22.55
|
-42.79
|
-49.52
|
17.15
|
22.9
|
34.6
|
53.1
|
Net margin
|
2.95%
|
-10.82%
|
-19.8%
|
-15.65%
|
3.52%
|
4.28%
|
6.01%
|
8.71%
|
EPS
2 |
0.5000
|
-1.880
|
-3.400
|
-3.050
|
0.8500
|
1.287
|
2.053
|
3.295
|
Free Cash Flow
1 |
-
|
-
|
0.765
|
-40.08
|
110.1
|
107.2
|
105.4
|
121.8
|
FCF margin
|
-
|
-
|
0.35%
|
-12.67%
|
22.61%
|
20.05%
|
18.32%
|
19.99%
|
FCF Conversion (EBITDA)
|
-
|
-
|
1.18%
|
-
|
82.27%
|
76.69%
|
66.82%
|
71%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
641.78%
|
468.16%
|
304.73%
|
229.38%
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/27/20
|
3/9/21
|
3/15/22
|
3/9/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
52.06
|
60.93
|
64.48
|
73.86
|
83.82
|
94.23
|
106.8
|
116.5
|
131.8
|
131.7
|
125.5
|
131.1
|
136.9
|
141.2
|
132.6
|
EBITDA
1 |
16.64
|
16.2
|
4.273
|
9.861
|
19.55
|
23.33
|
33.01
|
34.12
|
36.48
|
30.2
|
30.55
|
33.51
|
36.99
|
38.8
|
36.36
|
EBIT
1 |
-3.562
|
-23.72
|
-19.2
|
-12.91
|
-4.995
|
1.82
|
9.895
|
12.4
|
17.95
|
6.726
|
8.859
|
11.72
|
14.48
|
16.22
|
14.88
|
Operating Margin
|
-6.84%
|
-38.94%
|
-29.77%
|
-17.48%
|
-5.96%
|
1.93%
|
9.27%
|
10.64%
|
13.61%
|
5.11%
|
7.06%
|
8.94%
|
10.57%
|
11.49%
|
11.23%
|
Earnings before Tax (EBT)
1 |
-7.13
|
-30.85
|
-25.9
|
-18.82
|
-12.22
|
-5.728
|
2.165
|
5.249
|
11.51
|
0.947
|
3.086
|
6.098
|
8.954
|
10.79
|
8.885
|
Net income
1 |
-4.447
|
-24.33
|
-20.54
|
-15.33
|
-9.006
|
-4.65
|
1.033
|
5.838
|
9.534
|
0.749
|
2.404
|
4.814
|
7.086
|
8.548
|
7.019
|
Net margin
|
-8.54%
|
-39.93%
|
-31.85%
|
-20.76%
|
-10.74%
|
-4.93%
|
0.97%
|
5.01%
|
7.23%
|
0.57%
|
1.92%
|
3.67%
|
5.18%
|
6.06%
|
5.29%
|
EPS
2 |
-0.3700
|
-1.720
|
-1.270
|
-0.9400
|
-0.5500
|
-0.2800
|
0.0600
|
0.2900
|
0.4500
|
0.0400
|
0.1233
|
0.2567
|
0.4133
|
0.5000
|
0.3300
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/1/21
|
3/15/22
|
5/10/22
|
8/8/22
|
11/9/22
|
3/9/23
|
5/8/23
|
8/9/23
|
11/8/23
|
2/29/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
80.3
|
188
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
0.77
|
-40.1
|
110
|
107
|
105
|
122
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
6.64
|
6.14
|
2.56
|
8.88
|
8.87
|
9.6
|
9.7
|
12.7
|
Capex / Sales
|
3.21%
|
2.94%
|
1.18%
|
2.81%
|
1.82%
|
1.8%
|
1.69%
|
2.08%
|
Announcement Date
|
2/27/20
|
3/9/21
|
3/15/22
|
3/9/23
|
2/29/24
|
-
|
-
|
-
|
Last Close Price
65.5
USD Average target price
79.8
USD Spread / Average Target +21.83% Consensus |
1st Jan change
|
Capi.
|
---|
| +18.79% | 1.37B | | +26.47% | 664B | | +26.74% | 567B | | -6.33% | 354B | | +19.35% | 330B | | +4.23% | 286B | | +13.43% | 234B | | +4.71% | 199B | | -9.53% | 196B | | -4.04% | 148B |
Other Pharmaceuticals
|